Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.

Manol Jovani, Gionata Fiorino, Silvio Danese

Research output: Contribution to journalArticlepeer-review


Much work has been done to understand the molecular mechanisms underlying the inflammatory bowel diseases (IBD). IL-13 has emerged as an important cytokine effective in ulcerative colitis (UC) and fistulizing Crohn's disease (CD). IL-13 is a T helper 2-type cytokine with pleiotropic effects, involved in parasite expulsion, asthma pathophysiology, natural history of cancer and other human pathologies. Great interest has therefore been developed in inhibiting its function as a therapeutic intervention in these diseases. The multifunctional properties of IL-13, with particular emphasis on its role in both CD and UC, as well as current developing pharmacologic agents inhibiting the IL-13 signaling pathway have been reviewed. Anti-IL-13 agents seem to be promising therapeutic strategies for the future management of IBD and other human diseases.

Original languageEnglish
Pages (from-to)1444-1452
Number of pages9
JournalCurrent Drug Targets
Issue number12
Publication statusPublished - Nov 2013

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine


Dive into the research topics of 'Anti-IL-13 in inflammatory bowel disease: from the bench to the bedside.'. Together they form a unique fingerprint.

Cite this